We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Renalytix PLC | NASDAQ:RNLX | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0731 | 18.66% | 0.4649 | 0.34 | 0.75 | 0.4274 | 0.3918 | 0.409 | 120,792 | 05:00:07 |
From May 2023 to May 2024
By Stephen Nakrosis
Renalytix said the Food and Drug Administration has granted De Novo marketing authorization for the KidneyIntelX.dkd prognostic test.
Renalytix said the authorization "affirms KidneyIntelX as a first-in-class, artificial intelligence enabled prognostic testing platform to guide care management for adults with type 2 diabetes and early stage chronic (diabetic) kidney disease."
De Novo authorization provides a marketing pathway for novel medical devices, the FDA said.
Renalytix also said it believes the authorization will lead to increasing test adoption, expanding insurance coverage, and the pursuit of additional international regulatory approvals.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 29, 2023 18:43 ET (22:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Renalytix Chart |
1 Month Renalytix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
